Benefit of treatment of latent tuberculosis infection in individual patients

Fluegge, Keith

doi:10.1183/13993003.01946-2015

Eur Respir J

2016

DOI: 10.1183/13993003.01946-2015

|View full text |Cite

Benefit of treatment of latent tuberculosis infection in individual patients

Keith Fluegge

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Preprint1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Latent tuberculosis infection therapy in people living with human immunodeficiency virus infection

Lin

Tsai

et al. 2023

Preprint

View full text Add to dashboard Cite

Background The World Health Organization (WHO) suggests that some high-risk patient groups should receive latent tuberculosis infection (LTBI) screening and tuberculosis prevention treatment, including people living with human immunodeficiency virus (PLHIV). We performed an updated meta-analysis to compare the different LTBI therapeutic regimens for LTBI test-positive PLHIV. Methods We searched PubMed, Embase, Cochrane library, clinicaltrials.gov, and the International Clinical Trials Registry Platform for all literature and ongoing trials from their inception until November 30th, 2022. We performed a meta-analysis of the efficacy, adhesion rate, and severe adverse events; and graded the evidence quality. Results Nine studies were eligible, including two non-randomized studies (NRS) with 470 participants and seven randomized control trials (RCT)with 3,979 participants. The quality of evidence was very low for the results of the NRSs and low for the RCTs. Compared with placebo or non-treatment, both isoniazid (OR: 0.56; 95%CI 0.33-0.93) and rifamycin-based treatments (OR: 0.44; 95%CI 0.26-0.72) had efficacy for active TB prevention. Rifamycin-based regimens seem to have a better adhesion rate than isoniazid alone (RR: 1.11; 95%CI 1.04-1.19) and similar adverse events (RR: 0.73; 95%CI 0.49-1.09). Conclusions LTBI treatment decreased the active rate of TB in LTBI test-positive PLHIV. Rifamycin-based therapies may have a higher adhesion rate, while their efficacy and adverse events appear similar to isoniazid. More studies focusing on LTBI test-positive PLHIV participants would help gather high-quality evidence for decision-making.

show abstract

Latent tuberculosis infection therapy in people living with human immunodeficiency virus infection

Lin

Tsai

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Benefit of treatment of latent tuberculosis infection in individual patients

Cited by 1 publication

References 8 publications

Latent tuberculosis infection therapy in people living with human immunodeficiency virus infection

Latent tuberculosis infection therapy in people living with human immunodeficiency virus infection

Contact Info

Product

Resources

About